Considering the major role of VEGFR2 in VEGF-induced angiogenesis in human cancer, the finding of high VEGFR2 expression in HER2+ BRC provides scientific rationale to study clinical activity of therapeutic blockade of VEGFR2 in this clinically aggressive breast cancer subtype. Here, KDR is linked to breast carcinoma.